Faeth Therapeutics, Inc. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Faeth Therapeutics filed an 8-K on 2026-09-17 reporting Item 5.02 matters relating to departure of officers/directors and compensatory arrangements. The specific names, titles, dates of departure, dollar amounts, equity grants, and details of any new appointments or arrangements are not provided in the accessible filing header and document list. Full details require review of the actual 8-K exhibit.
Why this rating
Standard officer/director transition disclosure. Specifics unavailable in text provided; impact depends on role materiality relative to $7.1M market cap.
Extracted items
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.